@Article{info:doi/10.2196/69829,
author="Meyerson, Beth E
and Davis, Alissa
and Crosby, Richard A
and Linde-Krieger, Linnea B
and Brady, Benjamin R
and Carter, Gregory A
and Mahoney, Arlene N
and Frank, David
and Rothers, Janet
and Coffee, Zhanette
and Deuble, Elana
and Ebert, Jonathon
and Jablonsky, Mary F
and Juarez, Marlena
and Lee, Barbara
and Lorenz, Heather M
and Pava, Michael D
and Tinsely, Kristen
and Yousaf, Sana",
title="Methadone Patient Access to Collaborative Treatment: Protocol for a Pilot and a Randomized Controlled Trial to Establish Feasibility of Adoption and Impact on Methadone Treatment Delivery and Patient Outcomes",
journal="JMIR Res Protoc",
year="2025",
month="Apr",
day="15",
volume="14",
pages="e69829",
keywords="methadone; implementation; patient-centered treatment; opioid use disorder; posttraumatic stress symptoms; vicarious trauma",
abstract="Background: Access to methadone treatment can reduce opioid overdose death by up to 60{\%}, but US patient outcomes are suboptimal. Federally allowed methadone treatment accommodations during the COVID-19 public health emergency were not widely adopted. It is likely that staff-level characteristics such as trauma symptoms influence the adoption of treatment innovation. Objective: Methadone Patient Access to Collaborative Treatment (MPACT) is a 2-phased project (pilot and field trial) to develop and test a staff-level, multimodal intervention to increase staff adoption of low-barrier, patient-centered methadone treatment practices and ultimately improve treatment retention and patient outcomes. Methods: A pilot and national trial will measure implementation feasibility, acceptability, and effects of the MPACT intervention on treatment practice change, clinic culture, patient retention, and patient posttraumatic stress symptoms (PTSS). The pilot will be a single-arm 5.5-month pilot study of MPACT conducted in 2 Arizona methadone treatment clinics (rural and urban) among 100 patients and 22 staff. The national trial will be a 20-month cluster randomized trial conducted among 30 clinics, 600 patients (20 per clinic), and 480 staff (18 per clinic). Data will be gathered by staff and patient surveys and patient chart review. The primary study outcome is increased patient methadone treatment retention measured as (1) time to first treatment interruption from study enrollment; (2) active in treatment at enrollment, day 30, 60, 90, and 120; and (3) continuous days in treatment during the study period. Secondary study outcomes include reductions in vicarious trauma and PTSS among enrolled opioid treatment program staff and PTSS among enrolled patients. Results: The pilot study was funded by the National Institute on Drug Abuse (award R61DA059889, funded September 2023), and the field trial will be funded under the associated R33 mechanism in September 2025. The pilot study was completed in March 2025. The randomized controlled trial will begin in December 2025. Both the pilot and trial have been approved by the University of Arizona Human Subjects Protection Program and have been registered with the clinical trials network. Conclusions: The MPACT study will provide a foundation for an evidence-based, staff-level intervention aimed at improving patient retention in methadone treatment. Future studies should examine the individual components of MPACT to determine their differential contributions to the primary outcome of patient methadone treatment retention and to secondary outcomes of staff and patient reduction in stress symptoms. Trial Registration: ClinicalTrials.gov NCT06513728; https://clinicaltrials.gov/study/NCT06513728 and ClinicalTrials.gov NCT06556602; https://clinicaltrials.gov/study/NCT06556602 International Registered Report Identifier (IRRID): DERR1-10.2196/69829 ",
issn="1929-0748",
doi="10.2196/69829",
url="https://www.researchprotocols.org/2025/1/e69829",
url="https://doi.org/10.2196/69829",
url="http://www.ncbi.nlm.nih.gov/pubmed/40105313"
}